The invention relates to the use of herbal preparation, characterized by presence of 4 dominant compounds (carvacrol from about 35% to about 50%, y-terpinene from about 10% to about 30%, thymol from about 10% to about 25%, p-cymene from about 8% to about 20%, as expressed in % of total peak area in GC/MS chromatogram), obtained by mixing at least two essential oils from species selected from the group of genera Satureja L., Origanum L. and Thymus L., to prepare food supplement or medicament for treatment and prevention of gastric Helicobacter pylori infection in humans The mixture may be placed on liquid or solid carrier and capsulated in non gastro-resistant capsules. The invention also relates to dosage regiment of herbal preparation for treatment and prevention of patients with Helicobacter pylori infection which leads to successful eradication of bacteria without any side-effects.

Provided are topical analgesic gel compositions having relatively high payloads of menthol and camphor by micro-emulsion technology and methods of preparing topical analgesic gel compositions having relatively high payloads of menthol and camphor. Topical analgesic gel compositions may include from 12 to 16 wt. % menthol; from 4 to 8 wt. % camphor; from 0.1 to 2 wt. % carbomer; and 60 to 70 wt. % solvent. Topical analgesic gel compositions can have a viscosity from 60,000 to 110,000 centipoise.

Provided are topical analgesic gel compositions having relatively high payloads of menthol and camphor by micro-emulsion technology and methods of preparing topical analgesic gel compositions having relatively high payloads of menthol and camphor. Topical analgesic gel compositions may include from 12 to 16 wt. % menthol; from 4 to 8 wt. % camphor; from 0.1 to 2 wt. % carbomer; and 60 to 70 wt. % solvent. Topical analgesic gel compositions can have a viscosity from 60,000 to 110,000 centipoise.

An application of geraniol in preparation of formulation for promoting synthesis of Pseudomonas aeruginosa 3OC.sub.12-HSL signal molecules is provided. It was found that geraniol slightly inhibits growth of Pseudomonas aeruginosa PAO1 strain, but can significantly promote synthesis of the 3OC.sub.12-HSL signal molecules of the bacterium, and thus can be applied to preparation of formulation for promoting synthesis of the Pseudomonas aeruginosa 3OC.sub.12-HSL signal molecules.

A process can be used for preparing nano- or microparticles containing a carrier-polymer and a biologically active ingredient. The process is a solvent emulsion process involving an organic phase (OP) and an aqueous phase (AP) to form an emulsion. In the case of an oil-in-water emulsion (O/W), the organic phase (OP) contains the biologically active ingredient dissolved or dispersed therein. Alternatively, in the case of a water-in-oil emulsion (W.sub.1/O), the aqueous phase (AP) contains the biologically active ingredient dissolved or dispersed therein. The organic phase (OP) is saturated with the salt-containing aqueous phase (AP) and vice versa.

A process can be used for preparing nano- or microparticles containing a carrier-polymer and a biologically active ingredient. The process is a solvent emulsion process involving an organic phase (OP) and an aqueous phase (AP) to form an emulsion. In the case of an oil-in-water emulsion (O/W), the organic phase (OP) contains the biologically active ingredient dissolved or dispersed therein. Alternatively, in the case of a water-in-oil emulsion (W.sub.1/O), the aqueous phase (AP) contains the biologically active ingredient dissolved or dispersed therein. The organic phase (OP) is saturated with the salt-containing aqueous phase (AP) and vice versa.

The invention provides oral terpene cyclodextrin inclusion complex delivery vehicles, including formulations in which the cyclodextrin inclusion complex is provided together with enzyme having a cyclodextrin-degrading activity capable of digesting the cyclodextrin, so that upon delivery of the vehicle to a target the enzyme is activated and releases the guest molecule from the cyclodextrin cavity. In alternative aspects, these cyclodextrin inclusion complex delivery vehicles are for example provided in the form of time release formulations, for example for treatment of airway mucus dysfunction. Formulations are also provided with erectogenic efficacy.

The invention provides oral terpene cyclodextrin inclusion complex delivery vehicles, including formulations in which the cyclodextrin inclusion complex is provided together with enzyme having a cyclodextrin-degrading activity capable of digesting the cyclodextrin, so that upon delivery of the vehicle to a target the enzyme is activated and releases the guest molecule from the cyclodextrin cavity. In alternative aspects, these cyclodextrin inclusion complex delivery vehicles are for example provided in the form of time release formulations, for example for treatment of airway mucus dysfunction. Formulations are also provided with erectogenic efficacy.

A kit and method for providing a “second line of defense” against Corona Virus strains. The kit includes at least one nasal swab pre-moistened with an iodine solution, and at least one oral swab pre-moistened with a chlorhexidine solution. The iodine solution can be a solution of betadine 0.5-2.0%, or a povidone solution. The chlorhexidine solution is chlorhexidine 0.09% to 0.12%. The nasal swabs are preferably sealed in a resealable package. The oral swabs are preferably sealed in a separate resealable package. The kit can include alcohol swabs pre-moistened with 60%-70% Isopropyl Alcohol in a disposable sealed package. The method includes using at least one nasal swab pre-moistened with an iodine solution to apply the iodine solution to an inner surface within each of one's nostrils, and using at least one oral swab pre-moistened with chlorhexidine solution to apply the chlorhexidine solution to an inner surface of one's mouth.

A kit and method for providing a “second line of defense” against Corona Virus strains. The kit includes at least one nasal swab pre-moistened with an iodine solution, and at least one oral swab pre-moistened with a chlorhexidine solution. The iodine solution can be a solution of betadine 0.5-2.0%, or a povidone solution. The chlorhexidine solution is chlorhexidine 0.09% to 0.12%. The nasal swabs are preferably sealed in a resealable package. The oral swabs are preferably sealed in a separate resealable package. The kit can include alcohol swabs pre-moistened with 60%-70% Isopropyl Alcohol in a disposable sealed package. The method includes using at least one nasal swab pre-moistened with an iodine solution to apply the iodine solution to an inner surface within each of one's nostrils, and using at least one oral swab pre-moistened with chlorhexidine solution to apply the chlorhexidine solution to an inner surface of one's mouth.